San Diego-based Viking Therapeutics marked itself as a serious competitor during the weight loss drug market place in February soon after revealing promising details from a mid-phase trial of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when offered as being a weekly injection and in March the comp